Novo Nordisk's Conflicting Signals: A Chinese Green Light, a Downgrade, and a Buyback in Motion
Published on 08/29/2026 at 13:31 | Editorial boerse-global.de
The Danish pharmaceutical heavyweight spent last week quietly buying its own stock while a regulatory milestone in Beijing and a bearish call from Deutsche Bank competed for investors' attention. Between August 17 and 21, Novo Nordisk repurchased 1,045,000 B-shares at average prices ranging from 292.60 to 299.08 Danish kroner, bringing its total buyback tally since the program launched on February 4 to roughly 29.93 million shares at a combined cost of 8.39 billion kroner.
The company now holds 43,969,876 of its own B-shares, equivalent to one percent of its total share capital — a signal that management is willing to deploy capital defensively even as the stock faces persistent headwinds.
Beijing Opens a Door, Frankfurt Closes Another
The more consequential development for long-term holders came from China, where the National Medical Products Administration (NMPA) accepted the company's marketing application for the oral version of Wegovy. Novo Nordisk declined to offer a timeline for potential approval, but the formal acceptance marks a meaningful step in the race against Eli Lilly's oral candidate orforglipron on what is widely considered one of the largest potential obesity markets globally.
That progress landed in the same week as a downgrade from Deutsche Bank. On Thursday, analysts there moved their rating from "Hold" to "Sell" and trimmed the price target from 290 to 265 Danish kroner, citing persistent concerns about the company's ability to return to growth by 2027, intensifying competition from Eli Lilly, and the recent failure of the late-stage Ziltivekimab trial in the cardiovascular indication.
The market's response was muted. Shares closed Friday at EUR 39.41, down 0.6 percent on the day and roughly 13 percent lower over the past month. The stock now sits about a fifth below its 52-week high of EUR 54.86, set in late January.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Split on the Street
What makes the current moment particularly unusual is the degree of disagreement among major banks. JPMorgan, just days before Deutsche Bank's move, went in the opposite direction, raising its price target to 275 from 250 Danish kroner while maintaining a neutral stance. The bank cited improved growth prospects for Ozempic and Wegovy outside the United States.
Two major houses, nearly identical calendar weeks, diametrically opposed conclusions. The divergence underscores just how unsettled the debate over Novo Nordisk's growth trajectory has become.
Old News, New Noise
Some of the bearish narrative surrounding the stock deserves scrutiny. The FDA warning letter concerning inadequate reporting of side effects for Ozempic and Wegovy was issued back in early March — it is established history, not fresh damage. The company has said it is addressing the regulator's concerns.
Similarly, the situation involving Scholar Rock's decision to drop a Catalent facility in Indiana — a Novo Nordisk subsidiary — from its Apitegromab application has been circulating since early August. The formal withdrawal notice came toward the end of August, following an "Official Action Indicated" designation from the FDA at the plant. While not a direct approval setback for Novo Nordisk, it keeps the spotlight on manufacturing quality across the company's broader ecosystem, a topic that may give other partners pause.
Pipeline Progress Beneath the Surface
Operationally, the company continues to advance its clinical agenda. The OASIS-5 late-stage study, testing lower maintenance doses of the oral Wegovy pill in roughly 450 adults with obesity or overweight across 62 sites in the US and Europe, launched on August 12 and is scheduled to run until April 2028.
Earlier in the month, Novo Nordisk secured a preliminary injunction from a Dutch court in a semaglutide patent dispute against Ceban, adding another layer of protection against copycat products.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The pipeline also showed promise with Phase 1b/2a data for subcutaneous amycretin, demonstrating weight reductions of up to 24.3 percent at the 60-mg dose over 36 weeks. That data underpins the newly initiated Phase 3 AMAZE 1 study. At the EASL congress, the company presented new safety data for semaglutide 2.4 mg, including subgroup analyses of postmenopausal women and Japanese patients from the ESSENCE program.
A Stock for the Patient, Not the Impatient
The technical picture offers little clarity. The relative strength index sits at 43.3, suggesting neither oversold conditions nor euphoria — a market searching for direction rather than conviction.
What emerges is a two-sided story: regulatory and operational momentum on multiple fronts, weighed against unresolved questions about growth durability that have yet to be answered to the Street's satisfaction. The buyback program and the Chinese filing provide tangible support, but whether they can offset the skepticism embedded in Deutsche Bank's call will only become clear once the accepted application transforms into an actual approval process.
The Capital Markets Day on September 21 may offer management its best opportunity to translate operational substance into a convincing growth narrative for 2027. Until then, this remains a stock for investors with steady nerves — not those seeking quick resolution.
Ad
Novo Nordisk Stock: New Analysis - 29 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
